Moving beyond the traditional two-step approach for prognosis prediction: The BayeSarc model.
Gabriele Tinè(Fondazione IRCCS Istituto Nazionale dei Tumori), Rosalba Miceli(Fondazione IRCCS Istituto Nazionale dei Tumori), Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Toufik Bouhadiba(Institut Curie), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), Peter C. Ferguson(University of Toronto), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Anthony M. Griffin(Mount Sinai Hospital), Andrew J. Hayes(Royal Marsden NHS Foundation Trust), Jay S. Wunder(Sinai Health System), Sandro Pasquali(Fondazione IRCCS Istituto Nazionale dei Tumori), Dimitri Tzanis(Université Paris Cité)
Cited by 2
Related Papers
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
|The Lancet Oncology|2008|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k